Aztreonam News and Research

RSS
New clinical practice guideline published for adults with community acquired pneumonia

New clinical practice guideline published for adults with community acquired pneumonia

Green tea compound shows promise in tackling antibiotic resistance

Green tea compound shows promise in tackling antibiotic resistance

Natural antioxidant in green tea can help eliminate antibiotic-resistant bacteria

Natural antioxidant in green tea can help eliminate antibiotic-resistant bacteria

Microbiologists uncover how antibiotics help spread resistance

Microbiologists uncover how antibiotics help spread resistance

New combination antibiotic therapy overcomes pernicious infections caused by drug-resistant bacteria

New combination antibiotic therapy overcomes pernicious infections caused by drug-resistant bacteria

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Teflaro receives FDA approval for treatment of bacterial infections

Teflaro receives FDA approval for treatment of bacterial infections

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010